AntibioTx Announces New Board Members
COPENHAGEN, MAY 22, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members. Joining AntibioTx board of directors are Stig Loekke […]
AntibioTx Announces Phase I Study Results for ATx201
COPENHAGEN, APRIL 05, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today declared successful completion of a Phase I study with ATx201. The Study set out […]
AntibioTx Announces Reward of Grant Funding to Conduct Clinical Biomarker Study with ATx201
COPENHAGEN, MARCH 24 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to […]
AntibioTx Signs Dr. Philippe Prokocimer as Chief Medical Officer and Establishes US Subsidiary
AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders, has announced the appointment of Dr. Phillipe Prokocimer as new Chief Medical Officer. Dr. Prokocimer brings more than 30 years of […]
AntibioTx Expands Management Team with new VP of Drug Regulatory Affairs
COPENHAGEN, FEBRUARY 15, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders today announced that Lutz Wevelsiep, Ph.D. will be appointed as AntibioTx new VP of Drug Regulatory Affairs. […]
AntibioTx Invited to Present at Berlin Antimicrobial Conference
COPENHAGEN, NOVEMBER 14, 2016 – Worldwide we a see a need for action against AMR and AntibioTx is highly aware of something has to be done. The 10th Berlin Conference on Life Sciences […]
AntibioTx Concludes 28-day Repeat Dosing in Göttingen Minipigs with Positive Results
COPENHAGEN, SEPTEMBER 19, 2016 – A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a […]
AntibioTx Invited to Publish ATx201 Results at the ‘2nd Inflammatory Skin Disease Summit’ (New York)
COPENHAGEN, SEPTEMBER 06, 2016 – AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. The ‘2nd […]
AntibioTx Enters Collaboration with Dr. Keith Bostian to Establish Medicinal Chemistry Program
COPENHAGEN, AUGUST 19, 2016 – Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in […]
In vivo Efficacy Studies of ATx201 Compares Favorably with Marketed Products
COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten […]
